PARP activation is a characteristic of several pathological conditions and diseases in addition to cancer, and as such, there is considerable interest in evaluating PARP inhibitors for the treatment of diabetic retinopathy, cardiovascular disease, inflammation, and stroke [6], [15]. The gene discussed is PARP1; the disease is cancer.